Skip to main content

News

ACIP Recommendations for Pfizer-BioNTech COVID-19 Vaccine Use (including Special Populations)

CDC/MMWR

Following the FDA issuance of an Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine, the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for the prevention of COVID-19 in persons aged ≥16 years. 

Encouraging Rheumatology Fellowship Match for 2021

JJ Cush and ACR Press Release

The results of the National Residents Matching Program (NRMP) match in rheumatology are out and show that rheumatology fellowship was both competitive and highly sought after.

COVID-19 as a Leading Cause of Death in the USA

The exponential rise in deaths from the coronavirus (COVID-19) in the last several months is put into perspective by JAMA Viewpoint article noting that current US death rates of > 3000 per day from COVID-19 is greater than that seen in one day on September 11, 2001 (9/11 attacks, claimed 2988 lives) or by a fictional catastrophe of 15 Airbus 320 jetliners (150 passengers each) crashing daily.

Benlysta First Agent Approved for Lupus Nephritis

After the successful completion of the BLISS-LN trial and previewing the results at EULAR 2020 and ACR Convergence, GlaxoSmithKline announced yesterday that the FDA has approved belimumab (Benlysta) for use in adults with active lupus nephritis (LN) receiving background/standard therapy.

Filgotinib Bows Out of the RA Race in the USA

Gilead Sciences Inc announced yesterday that it has decided not to pursue the an rheumatoid arthritis (RA) indicatin for its once daily oral JAK inhibitor, filgotinib (also named Jyseleca).

Consensus Recommendations on JAK Inhibitor Use

A steering committee and task force was convened to develop recommendations for the use of Janus kinase (JAK) inhibitors in the treatment of immune-mediated inflammatory diseases (IMID).

Lung Cancer Survival With Autoimmune Disease

Lung cancer risk is often increased with inflammation and autoimmune disease; a recent analysis suggests that patients with autoimmune disease do not have worse survival, even though they may have received less than the standard-of-care treatments.

COVID Risks in Systemic Autoimmune Patients

There have been conflicting reports of whether rheumatic patients have greater risks once they are infected with COVID-19. This claims cohort analysis suggests a mixed picture. 

Four Lifestyle Changes to Prevent Gout

MedPage Today

JAMA Open Network reports that reducing four particular risk factors for gout could slash incident cases in men.

RheumNow Podcast – Stop These COVID Mistakes (12.11.20)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

New Lyme Disease Guidelines

2020 evidence-based clinical practice guideline for the prevention, diagnosis, and treatment of Lyme disease was cooperatively developed the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR).

Rheumatic Disease and COVID-19: Who Is at Risk?

MedPage Today

Patients with rheumatic and inflammatory diseases who develop COVID-19 share risk factors for severe disease with the larger population, including older age, male sex, obesity, and hypertension, but also are at increased risk if they are on corticosteroids, French investigators reported.

×